Skip to main content

3 Result(s)

within Hélène Parisé Remove this filter

and

  1. Article

    Open Access

    Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA

    This study aimed to assess the budget impact of introducing fixed-duration mosunetuzumab as a treatment option for adult patients with relapsed or refractory follicular lymphoma after at least two prior system...

    Shih-Wen Lin, Sheila Shapouri, Hélène Parisé, Eric Bercaw, Mei Wu… in PharmacoEconomics (2024)

    Download PDF (1241 KB) View Article

  2. Article

    Open Access

    Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States

    This study aimed to assess the total cost of care (TCC) and budget impact of introducing 12-month fixed duration venetoclax + obinutuzumab (VEN+G) as first-line treatment for chronic lymphocytic leukemia (CLL)...

    Sang Kyu Cho, Beenish S. Manzoor, Kavita R. Sail, Hélène Parisé… in PharmacoEconomics (2020)

    Download PDF (1299 KB) View Article

  3. No Access

    Article

    Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States

    New treatments for chronic hepatitis C virus (HCV) are highly effective in patients coinfected with human immunodeficiency virus (HIV). This study estimated the cost-effectiveness of treatments for genotype 1 ...

    Sammy Saab, Suchin Virabhak, Hélène Parisé, Scott Johnson… in Advances in Therapy (2016)